Literature DB >> 29731420

Performance of T2 Maps in the Detection of Prostate Cancer.

Aritrick Chatterjee1, Ajit Devaraj2, Melvy Mathew1, Teodora Szasz3, Tatjana Antic4, Gregory S Karczmar1, Aytekin Oto5.   

Abstract

RATIONALE AND
OBJECTIVES: This study compares the performance of T2 maps in the detection of prostate cancer (PCa) in comparison to T2-weighted (T2W) magnetic resonance images.
MATERIALS AND METHODS: The prospective study was institutional review board approved. Consenting patients (n = 45) with histologic confirmed PCa underwent preoperative 3-T magnetic resonance imaging with or without endorectal coil. Two radiologists, working independently, marked regions of interests (ROIs) on PCa lesions separately on T2W images and T2 maps. Each ROI was assigned a score of 1-5 based on the confidence in accurately detecting cancer, with 5 being the highest confidence. Subsequently, the histologically confirmed PCa lesions (n = 112) on whole-mount sections were matched with ROIs to calculate sensitivity, positive predictive value (PPV), and radiologist confidence score. Quantitative T2 values of PCa and benign tissue ROIs were measured.
RESULTS: Sensitivity and confidence score for PCa detection were similar for T2W images (51%, 4.5 ± 0.8) and T2 maps (52%, 4.5 ± 0.6). However, PPV was significantly higher (P = .001) for T2 maps (88%) compared to T2W (72%) images. The use of endorectal coils nominally improved sensitivity (T2W: 55 vs 47%, T2 map: 54% vs 48%) compared to the use of no endorectal coils, but not the PPV and the confidence score. Quantitative T2 values for PCa (105 ± 28 milliseconds) were significantly (P = 9.3 × 10-14) lower than benign peripheral zone tissue (211 ± 71 milliseconds), with moderate significant correlation with Gleason score (ρ = -0.284).
CONCLUSIONS: Our study shows that review of T2 maps by radiologists has similar sensitivity but higher PPV compared to T2W images. Additional quantitative information obtained from T2 maps is helpful in differentiating cancer from normal prostate tissue and determining its aggressiveness.
Copyright © 2019 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T2 map; T2-weighted; confidence score; prostate cancer

Mesh:

Year:  2018        PMID: 29731420      PMCID: PMC6215527          DOI: 10.1016/j.acra.2018.04.005

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  23 in total

1.  Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate.

Authors:  P Gibbs; D J Tozer; G P Liney; L W Turnbull
Journal:  Magn Reson Med       Date:  2001-12       Impact factor: 4.668

2.  Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study.

Authors:  Matthew D Greer; Anna M Brown; Joanna H Shih; Ronald M Summers; Jamie Marko; Yan Mee Law; Sandeep Sankineni; Arvin K George; Maria J Merino; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  J Magn Reson Imaging       Date:  2016-07-08       Impact factor: 4.813

3.  In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI.

Authors:  G P Liney; L W Turnbull; M Lowry; L S Turnbull; A J Knowles; A Horsman
Journal:  Magn Reson Imaging       Date:  1997       Impact factor: 2.546

4.  Characterization of prostate cancer using T2 mapping at 3T: a multi-scanner study.

Authors:  A Hoang Dinh; R Souchon; C Melodelima; F Bratan; F Mège-Lechevallier; M Colombel; O Rouvière
Journal:  Diagn Interv Imaging       Date:  2014-12-23       Impact factor: 4.026

5.  Prostate cancer: multiparametric MRI for index lesion localization--a multiple-reader study.

Authors:  Andrew B Rosenkrantz; Fang-Ming Deng; Sooah Kim; Ruth P Lim; Nicole Hindman; Thais C Mussi; Bradley Spieler; Jason Oaks; James S Babb; Jonathan Melamed; Samir S Taneja
Journal:  AJR Am J Roentgenol       Date:  2012-10       Impact factor: 3.959

6.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

Review 7.  The role of MRI in prostate cancer active surveillance.

Authors:  Linda M Johnson; Peter L Choyke; William D Figg; Baris Turkbey
Journal:  Biomed Res Int       Date:  2014-11-30       Impact factor: 3.411

8.  Impact of the use of an endorectal coil for 3 T prostate MRI on image quality and cancer detection rate.

Authors:  Josephin Gawlitza; Martin Reiss-Zimmermann; Gregor Thörmer; Alexander Schaudinn; Nicolas Linder; Nikita Garnov; Lars-Christian Horn; Do Hoang Minh; Roman Ganzer; Jens-Uwe Stolzenburg; Thomas Kahn; Michael Moche; Harald Busse
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

9.  Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Authors:  Carsten Stephan; Harry Rittenhouse; Xinhai Hu; Henning Cammann; Klaus Jung
Journal:  EJIFCC       Date:  2014-04-28

Review 10.  Multi-parametric MRI imaging of the prostate-implications for focal therapy.

Authors:  James S Wysock; Herbert Lepor
Journal:  Transl Androl Urol       Date:  2017-06
View more
  11 in total

1.  Clinical utility of combined T2-weighted imaging and T2-mapping in the detection of prostate cancer: a multi-observer study.

Authors:  Chau Hung Lee; Matthias Taupitz; Patrick Asbach; Julian Lenk; Matthias Haas
Journal:  Quant Imaging Med Surg       Date:  2020-09

2.  Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings.

Authors:  Aritrick Chatterjee; Crystal Mercado; Roger M Bourne; Ambereen Yousuf; Brittany Hess; Tatjana Antic; Scott Eggener; Aytekin Oto; Gregory S Karczmar
Journal:  Radiology       Date:  2021-11-09       Impact factor: 11.105

3.  Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.

Authors:  Young Sub Lee; Moon Hyung Choi; Young Joon Lee; Dongyeob Han; Dong-Hyun Kim
Journal:  Br J Radiol       Date:  2021-08-20       Impact factor: 3.039

Review 4.  Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.

Authors:  Durgesh Kumar Dwivedi; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

Review 5.  MR fingerprinting of the prostate.

Authors:  Wei-Ching Lo; Ananya Panda; Yun Jiang; James Ahad; Vikas Gulani; Nicole Seiberlich
Journal:  MAGMA       Date:  2022-04-13       Impact factor: 2.533

Review 6.  New prostate MRI techniques and sequences.

Authors:  Aritrick Chatterjee; Carla Harmath; Aytekin Oto
Journal:  Abdom Radiol (NY)       Date:  2020-12

7.  T2 mapping for the characterization of prostate lesions.

Authors:  Tobias Hepp; Laura Kalmbach; Manuel Kolb; Petros Martirosian; Tom Hilbert; Wolfgang M Thaiss; Mike Notohamiprodjo; Jens Bedke; Konstantin Nikolaou; Arnulf Stenzl; Stephan Kruck; Sascha Kaufmann
Journal:  World J Urol       Date:  2022-03-31       Impact factor: 3.661

Review 8.  Rapid MR relaxometry using deep learning: An overview of current techniques and emerging trends.

Authors:  Li Feng; Dan Ma; Fang Liu
Journal:  NMR Biomed       Date:  2020-10-15       Impact factor: 4.478

9.  Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results.

Authors:  Lisa C Adams; Keno K Bressem; Phillipp Jurmeister; Ute L Fahlenkamp; Bernhard Ralla; Guenther Engel; Bernd Hamm; Jonas Busch; Marcus R Makowski
Journal:  Cancer Imaging       Date:  2019-06-07       Impact factor: 3.909

10.  Synthetic MRI for Radiotherapy Planning for Brain and Prostate Cancers: Phantom Validation and Patient Evaluation.

Authors:  Pierrick Gouel; Sebastien Hapdey; Arthur Dumouchel; Isabelle Gardin; Eva Torfeh; Pauline Hinault; Pierre Vera; Sebastien Thureau; David Gensanne
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.